Rotavirus serotype G9 is associated with more-severe disease in Latin America.
The association between rotavirus serotypes and severity is not well established. Analysis of a clinical trial conducted in Latin America points at more-severe disease associated with serotype G9. Thus, demonstration of efficacy against G9 will be an important asset of any rotavirus vaccine to be introduced into a Latin American country or any country where G9 has been shown to be prevalent.
Linhares
A C
AC
Instituto Evandro Chagas, Secretaria de Vigilância em Saúde, Ministério da Saúde, Belém, Brazil. alexandrelinhares@iec.pa.gov.br
Verstraeten
Thomas
T
Wolleswinkel-van den Bosch
Judith
J
Clemens
Ralf
R
Breuer
Thomas
T
D003968:Diarrhea, Infantile / Q000821:virology; D005260:Female; D005759:Gastroenteritis / Q000821:virology; D006801:Humans; D007223:Infant; D007843:Latin America / Q000453:epidemiology; D008297:Male; D015995:Prevalence; D012401:Rotavirus / Q000145:classification*; D012400:Rotavirus Infections / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology*; D022243:Rotavirus Vaccines / Q000008:administration & dosage; D012703:Serotyping; D012720:Severity of Illness Index
D022243:Rotavirus Vaccines